论文部分内容阅读
目的 观察重组人生长激素治疗肝硬变低蛋白血症的疗效。方法 随机选择 30例血清蛋白 <30 g/L、A/G <1 0的肝炎后肝硬变 (活动期 )病人 ,在常规治疗基础上加用重组人生长激素 4IU ,皮下注射 ,每日 1次 ,10d为 1个疗程。结果 治疗后 ,病人临床症状明显改善 ,腹水明显减少 ,下肢浮肿消退 ,血清白蛋白明显增加 ,球蛋白明显下降 ,A/G比值升高 ,停药 2周后白蛋白增加更为明显。结论 在综合治疗基础上使用重组人生长激素 ,能改善肝炎后肝硬变 (活动期 )病人蛋白合成功能 ,改善低蛋白血症和营养状况。
Objective To observe the effect of recombinant human growth hormone on cirrhosis and hypoproteinemia. Methods Thirty patients with post-hepatitis cirrhosis (active stage) with serum protein <30 g / L and A / G <10 were randomly selected and treated with recombinant human growth hormone 4IU on the basis of conventional treatment. Times, 10d for a course of treatment. Results After treatment, the clinical symptoms of patients were significantly improved, ascites decreased significantly, edema of lower extremities subsided, serum albumin increased significantly, globulin decreased significantly, A / G ratio increased, and albumin increased more obviously after 2 weeks of drug withdrawal. Conclusions The use of rhGH on the basis of comprehensive treatment can improve the protein synthesis and improve the hypoalbuminemia and nutritional status in patients with posthepatitic cirrhosis (active stage).